Valle Franco 4
4 · Eidos Therapeutics, Inc. · Filed Jan 13, 2021
Insider Transaction Report
Form 4
Valle Franco
Senior Vice President, Finance
Transactions
- Exercise/Conversion
Common Stock
2021-01-11$7.24/sh+1,500$10,860→ 1,500 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-01-12−1,747→ 24,350 totalExercise: $7.24Exp: 2028-05-06→ Common Stock (1,747 underlying) - Sale
Common Stock
2021-01-12$125.44/sh−1,747$219,152→ 0 total - Sale
Common Stock
2021-01-11$125.61/sh−1,500$188,408→ 0 total - Exercise/Conversion
Common Stock
2021-01-12$7.24/sh+1,747$12,648→ 1,747 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-01-11−1,500→ 26,097 totalExercise: $7.24Exp: 2028-05-06→ Common Stock (1,500 underlying)
Footnotes (1)
- [F1]The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer.